Table 1.
Study Name | Drug | Phase | Malignancy | First line | Arm 1 | Arm 2 | Arm 3 | Patient’ number | Age median | Age range | Age mean | n (%) < 65 y | n (%) ≥ 65 y | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rittmeyer 2016 [33] | OAK | Atezolizumab | 3 | NSCLC | N | Atezolizumab 1200 mg Q 3 W | Docetaxel 75 mg/m2 Q 3 W |
850 | 64 | 33–85 | 63 | 453 (53) | 397 (47) | |
Fehrenbacher 2016 [26, 34] | POPLAR | Atezolizumab | 2 | NSCLC | N | Atezolizumab 1200 mg Q 3 W | Docetaxel 75 mg/m2 Q 3 W |
287 | 62 | 36–84 | 61.5 | 174 (61) | 113 (39) | |
Brahmer 2015 [5] | Checkmate-017 | Nivolumab | 3 | S-NSCLC | N | Nivolumab 3 mg/kg Q 2 W | Docetaxel 75 mg/m2 Q 3 W |
272 | 63 | 39–85 | 63 | 152 (56) | 120 (44) | |
Borghaei 2015 [6] | Checkmate-057 | Nivolumab | 3 | NS-NSCLC | N | Nivolumab 3 mg/kg Q 2 W | Docetaxel 75 mg/m2 Q 3 W |
582 | 62 | 21–85 | NR | 339 (58) | 243 (42) | |
Motzer 2015 [4] | Checkmate-025 | Nivolumab | 3 | RCC | N | Nivolumab 3 mg/kg Q 2 W | Everolimus 10 mg daily | 821 | 62 | 18–88 | 61.3 | 497 (61) | 324 (39) | |
Robert 01–2015 [29] | Checkmate-066 | Nivolumab | 3 | Melanoma | Y | Nivolumab 3 mg/kg Q 2 W |
Dacarbazine 1000 mg/m2 Q 3 W |
418 | 65 | 18–87 | 62.7 | 200 (48) | 218 (52) | |
Ferris 2016 [2] | Checkmate-141 | Nivolumab | 3 | H&N | N | Nivolumab 3 mg/kg Q 2 W |
Chemotherapy | 361 | 60 | 28–83 | 59.1 | 248 (69) | 113 (31) | |
Herbst 2016 [8] | Keynote-010 | Pembrolizumab | 2/3 | NSCLC | N | Pembrolizmab 2 mg/kg Q 3 W |
Pembrolizumab 10 mg/kg Q 3 W | Docetaxel 75 mg/m2 Q 3 W |
1033 | NR | NR | 62 | 604 (58) | 429 (42) |
Robert 06–2015 [9] | Keynote-006 | Pembrolizumab | 3 | Melanoma | N | Pembrolizumab 10 mg/kg Q 2 W |
Pembrolizumab 10 mg/kg Q 3 W |
Ipilimumab 3 mg/kg Q 3 W |
834 | NR | NR | 60.3 | 467 (56) | 367 (44) |